Navigation Links
INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model
Date:10/6/2010

INTERCIM Received a New Patent for a Non-statistical Approach... -- ST. PAUL, Minnesota and PARIS, October 6, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Internet Technology, Computer Electronics, Computer Software, Biotechnology, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model

   

Company Awarded Patent # 7,617,171 B2

ST. PAUL, Minnesota and PARIS, October 6, 2010 /PRNewswire/ -- Intercim, LLC, a global leader in manufacturing operation management (MOM) software, announced it has been awarded a patent called "Process for the iterative construction of an explanatory model".

This patented process is a key component of the Intercim Operations Intelligence technology and will help industrial manufacturers and life sciences researchers in two ways: unlike a statistics-based approach, it reuses existing information to optimize the length and cost of an experiment plan and it gives a quick and effective way to confirm the reliability of a discovery with only a few experiments.

This approach enables Pertinence Suite's users to get, much faster, a more reliable explanatory model even with limited data points available in a highly multi-dimensional non-euclidian space.

"This approach seems much easier to adopt than other standard Design of Experiment techniques, because we can analyze simultaneously the influence of many design parameters without statistical hypotheses. Thanks to the Interactive Experiment Planning of Process Rule Discovery(TM), we have reduced our need for physical experiments by 50% and sometimes more," says Dominique Veret, former Head of Development at Siemens Automotive Hydraulics, now Continental.

In the last 18 months, Intercim has received several additional patents which validate the uniqueness of Intercim's logic-based analytics for rule discovery and rule-based real-time predictions on complex systems and industrial processes. The announcement of this latest patent further demonstrates the unprecedented value proposition that Intercim offers to the market in terms of Operations Intelligence. John Todd, Intercim's CEO adds, "This patent confirms that Intercim truly offers a unique and high value-add capability. This latest Patent award helps validate Intercim's contribution to improved complex system understanding, manufacturing productivity and cycle time optimization for our key markets: Aerospace & Defense, Automotive and Life Sciences."

About Intercim

Intercim has a 27-year history of helping advanced and highly regulated manufacturers reach their business goals through best in class software solutions. Early 2009, Dassault Systemes a world leader Product Lifecycle Management took a minority position in Intercim. For the first time, the combination of Intercim's software capabilities with the virtual experience provided by Dassault Systemes' solutions allows this type of mission-critical collaboration and knowledge sharing. Intercim serves industry-leading customers such as Boeing, EADS, Areva, Intel, Sanofi-Pasteur, BMW, and Honeywell.


'/>"/>
SOURCE Intercim
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
2. MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners
3. MIT is pleased to announce that it has received clearance by FINRA to be listed on the OTC Bulletin Board "MDLH.OB"
4. MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
5. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
6. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
7. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
8. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
9. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
10. PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKessons Patent Application
11. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):